期刊
MOLECULAR THERAPY
卷 22, 期 3, 页码 535-546出版社
CELL PRESS
DOI: 10.1038/mt.2013.273
关键词
-
资金
- National Institutes of Health (NIH) [R01 HL 109442, NIH R01 HL 107904, EY021752]
- Bill and Melinda Gates Foundation Global Health grant [OPP 1031406]
- Juvenile Diabetes Research Foundation [17-2011-286]
- American Diabetes Association, American Heart Association, Research to Prevent Blindness
Delivering neurotherapeutics to target brain-associated diseases is a major challenge. Therefore, we investigated oral delivery of green fluorescence protein (GFP) or myelin basic protein (MBP) fused with the transmucosal carrier cholera toxin B subunit (CTB), expressed in chloroplasts (bioencapsulated within plant cells) to the brain and retinae of triple transgenic Alzheimer's disease (3xTgAD) mice, across the blood-brain barriers (BBB) and blood-retinal barriers (BRB). Human neuroblastoma cells internalized GFP when incubated with CTB-GFP but not with GFP alone. Oral delivery of CTB-MBP in healthy and 3xTgAD mice shows increased MBP levels in different regions of the brain, crossing intact BBB. Thioflavin S-stained amyloid plaque intensity was reduced up to 60% by CTB-MBP incubation with human AD and 3xTgAD mice brain sections ex vivo. Amyloid loads were reduced in vivo by 70% in hippocampus and cortex brain regions of 3xTgAD mice fed with bioencapsulated CTB-MBP, along with reduction in the ratio of insoluble amyloid beta 42 (A beta(42)) to soluble fractions. CTB-MBP oral delivery reduced A beta(42) accumulation in retinae and prevented loss of retinal ganglion cells in 3xTgAD mice. Lyophilization of leaves increased CTB-MBP concentration by 17-fold and stabilized it during long-term storage in capsules, facilitating low-cost oral delivery of therapeutic proteins across the BBB and BRB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据